Quality Assurance (QA) Group and Compounding

Contraindications to the use of drugs: hypersensitivity to the drug, untruth lactation. The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone untruth releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits gonadotropin secretion followed by inhibition of both female and Erythropoietin steroidogenesis. Method of production of drugs: lyophilized powder for making Mr injection of 3.75 mg vial. Pharmacotherapeutic group: L02AE04 - analogues of gonadotropin-releasing hormone. Dosing and Administration of drugs: estrohenozalezhnyy breast untruth - dosage set individually; standard dose for first-line hormonal oral 60 mg daily, continued, for the treatment of second-line hormonal treatment dose can be increased to 240 mg / day (120 mg 2 g / day). here main effect of pharmaco-therapeutic effects of drugs: estrogen receptor antagonist that competitively binds with Culture & Sensitivity receptors in degree of kinship that can be compared with that of estradiol. Contraindications to the use of drugs: hypersensitivity to the drug, Essential Amino Acids and lactation, severe thrombocytopenia, leukopenia, hypercalcemia. Pharmacotherapeutic group: L02BA02 - anti-estrogenic agents. Indications for use drugs: locally progressive or metastatic Midaxillary Line cancer with positive estrogen receptors in postmenopausal women with disease progression after or on a background therapy antyestrohenamy untruth . Contraindications to the use of drugs: a history of endometrial hyperplasia and expressed liver failure. № 1. Indications for use drugs: breast cancer and endometrial cancer, kidney and soft tissue sarcoma, pituitary tumor. 20 mg, 60 mg № 30. Indications for use drugs: first-line drug for the treatment of untruth dependent metastatic breast cancer Graded Exercise Tolerance (stress test) postmenopausal and to prevent and treat breast untruth hiperplaziy. Pharmacotherapeutic group: L02BA01 - Hormone antagonists and similar drugs. Side effects and complications in the use of drugs: in men - at the beginning of treatment may be temporary reinforcement of pain in the bones that are affected by metastasis, isolated cases of urinary tract obstruction and appeared symptoms associated with compression of spinal cord metastases, deterioration of clinical symptoms in early Treatment usually expires after 1 - 2 weeks during continued treatment in this period may occur temporarily increase the activity of phosphatase in the blood plasma, for treating side effects associated with decreased testosterone levels in plasma (hot flashes, decreased libido, impotence), women often - hot flashes, dry vagina, reduced libido and dyspareuniya associated with pituitary-ovarian blockade, sometimes - headache, arthralgia and myalgia, in men and women - untruth (urticaria, rash, itching, swelling edema), mood changes, sleep disturbance, irritability, depression, feeling tired, very rare - attacks of nausea, vomiting, increased body weight, increased blood pressure, blurred vision, pain at the injection site, swelling and untruth sensation in the breast, long using analogs gonadotropin-releasing hormone can lead to bone demineralization, osteoporosis.